Edgewise Therapeutics (EWTX) EBIT (2020 - 2026)

Edgewise Therapeutics has disclosed EBIT across 7 years of filings, most recently posting -$54.1 million for Q1 2026.

• EBIT for Q1 2026 came in at -$54.1 million, down 17.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$199.6 million (down 17.36% YoY), and the FY2025 annual result was -$191.4 million, down 20.51% from the prior year.
• EBIT came in at -$54.1 million for Q1 2026 at Edgewise Therapeutics, up from -$56.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$14.8 million in Q1 2022 to a low of -$56.0 million in Q4 2025.
• The 5-year median for EBIT is -$34.8 million (2024), against an average of -$34.7 million.
• Across the five-year window, EBIT sank 116.22% in 2022 and fell 11.82% in 2025, its largest moves.
• Edgewise Therapeutics' EBIT stood at -$22.1 million in 2022, then tumbled by 53.37% to -$33.9 million in 2023, then plunged by 34.49% to -$45.5 million in 2024, then retreated by 22.92% to -$56.0 million in 2025, then rose by 3.33% to -$54.1 million in 2026.
• The last three EBIT figures came in at -$54.1 million (Q1 2026), -$56.0 million (Q4 2025), and -$46.9 million (Q3 2025), per Business Quant data.